|Institutional Source||Beutler Lab|
|Gene Name||E1A binding protein p300|
|Essential gene?||Essential (E-score: 1.000)|
|Stock #||R6292 (G1)|
|Chromosomal Location||81585351-81652077 bp(+) (GRCm38)|
|Type of Mutation||unclassified|
|DNA Base Change (assembly)||T to A at 81616734 bp (GRCm38)|
|Amino Acid Change|
|Ref Sequence||ENSEMBL: ENSMUSP00000145639 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000068387] [ENSMUST00000206936]|
AA Change: M545K
AA Change: M545K
|Meta Mutation Damage Score||0.0754|
|Coding Region Coverage||
|Validation Efficiency||100% (50/50)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]
PHENOTYPE: Homozygotes for a targeted null mutation exhibit defects of the heart, lung, and small intestine and die at midgestation; heterozygotes also show some embryonic loss. Heterozygotes for an acetyltransferase-negative mutation die by the neonatal period. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ep300||
(F):5'- AGCCTAGTGACATGACTTGGG -3'
(R):5'- CTCTTATGAATGATACATGCCACAGTC -3'
(F):5'- AAGAATTCACTCTCATCCTTCATAAG -3'
(R):5'- TGGAACTCACTCTGTAGACCAGG -3'